Skip to content
DataLookout
Menu

NCT07927023

A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

StatusNot Yet Recruiting
PhaseNot specified
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Real World Progression Free Survival (rwPFS)
Timeframe: From the index date through the end of the study period, approximately 6 months.
Overall Survival (OS)
Timeframe: From the index date through the end of the study period, approximately 6 months.
Time to next treatment (TTNT)
Timeframe: From the index date through the end of the study period, approximately 6 months.

Arms and interventions

Elranatamab

Patients treated with elranatamab from the MagnetisMM-5 trial

Standard of care

Patients treated with standard-of-care therapies from real-world data source

Drugs: Elranatamab, Standard of Care